NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
Phase 2
Withdrawn
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype
- Interventions
- Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingProcedure: Surgical Procedure
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT06328036
Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Phase 2
Suspended
- Conditions
- Recurrent Glioblastoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingProcedure: Surgical Procedure
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 184
- Registration Number
- NCT06325683
- Locations
- 🇺🇸
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland, Maine, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
Not Applicable
Suspended
- Conditions
- OverweightObesity
- Interventions
- Other: Low-carbohydrate DietOther: Low-fat Diet
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-05-15
- Target Recruit Count
- 13
- Registration Number
- NCT06325722
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Phase 2
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 147
- Registration Number
- NCT06317649
- Locations
- 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Kaiser Permanente Dublin, Dublin, California, United States
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2
Recruiting
- Conditions
- B Acute Lymphoblastic LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: FDG-Positron Emission TomographyProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT06317662
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Albany Medical Center, Albany, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Phase 2
Recruiting
- Conditions
- Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm
- Interventions
- Procedure: Biopsy ProcedureOther: Electronic Health Record ReviewProcedure: Biospecimen CollectionOther: Immunohistochemistry Staining MethodProcedure: Computed TomographyDrug: Enfortumab VedotinProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 500
- Registration Number
- NCT06311214
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Phase 2
Recruiting
- Conditions
- Recurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT06311227
- Locations
- 🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
Phase 2
Active, not recruiting
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT06308822
- Locations
- 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
Phase 2
Active, not recruiting
- Conditions
- Refractory Multiple MyelomaAdvanced Malignant Solid NeoplasmRefractory LymphomaAdvanced LymphomaHematopoietic and Lymphoid Cell NeoplasmRefractory Malignant Solid Neoplasm
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Echocardiography TestProcedure: Multigated Acquisition ScanProcedure: Radiologic Examination
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT06303167
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 160
- Registration Number
- NCT06303193
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath